| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705237 | Ophthalmology | 2017 | 10 Pages |
Abstract
These studies demonstrated the clinical benefits of nepafenac 0.3% over vehicle in reducing the risk of postoperative ME, with the integrated analysis showing improved BCVA after cataract surgery in patients with diabetic retinopathy, with no unanticipated safety events.
Keywords
FDANSAIDNPDRIOLFASBCVAiOpTEAECMEMacular edemacystoid macular edemaOctbest-corrected visual acuityfull analysis setOptical coherence tomographyVisual acuitystandard errornonsteroidal anti-inflammatory drugspectral-domainper protocolnonproliferative diabetic retinopathyFood and Drug Administrationadverse eventtreatment-emergent adverse eventconfidence intervalIntraocular pressureintraocular lens
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Rishi P. MD, Robert MD, Joseph MD, Kevin MD, Ayala MD, Alexis MD, PhD, Giovanni MD, Guadalupe MD, Louis MD, Satish MD, Liza MS, Adeniyi PhD, Glenn J. MD,